Health Catalyst's (HCAT) "Neutral" Rating Reaffirmed at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald reaffirmed its “neutral” rating on Health Catalyst (NASDAQ: HCAT), while several other brokerages also issued cautious views, leaving the stock with a consensus “Hold” rating and an average target price of $2.80.
• Analysts recently cut price targets at multiple firms, including Citigroup, Wells Fargo, Stifel, and Stephens, reflecting softer expectations for the company’s shares.
• Health Catalyst reported Q1 earnings of $0.08 per share, missing estimates, though revenue came in slightly above expectations at $74.68 million; the stock opened at $1.49 and remains well below its 52-week high.

Health Catalyst (NASDAQ:HCAT - Get Free Report)'s stock had its "neutral" rating reaffirmed by research analysts at Cantor Fitzgerald in a research note issued on Monday,Benzinga reports.

Several other brokerages have also commented on HCAT. Citigroup lowered their price objective on shares of Health Catalyst from $2.75 to $1.75 and set a "neutral" rating on the stock in a research report on Friday, March 13th. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $1.00 price target (down from $5.00) on shares of Health Catalyst in a report on Wednesday, March 18th. Raymond James Financial set a $3.00 price objective on Health Catalyst in a report on Friday, March 13th. Stifel Nicolaus lowered their target price on Health Catalyst from $3.75 to $2.00 and set a "hold" rating on the stock in a research note on Friday, March 13th. Finally, Stephens dropped their price target on Health Catalyst from $3.50 to $2.00 and set an "equal weight" rating on the stock in a research report on Friday, March 13th. Four investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Health Catalyst presently has a consensus rating of "Hold" and an average target price of $2.80.

Health Catalyst Stock Performance

Shares of HCAT opened at $1.49 on Monday. The stock has a 50 day moving average of $1.37 and a 200 day moving average of $2.08. The company has a market capitalization of $109.50 million, a price-to-earnings ratio of -0.59 and a beta of 1.63. Health Catalyst has a 12 month low of $0.96 and a 12 month high of $4.74. The company has a current ratio of 1.89, a quick ratio of 1.89 and a debt-to-equity ratio of 0.62.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.02). The business had revenue of $74.68 million during the quarter, compared to the consensus estimate of $73.99 million. Health Catalyst had a negative net margin of 57.20% and a negative return on equity of 4.30%. As a group, sell-side analysts forecast that Health Catalyst will post -0.28 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HCAT. AQR Capital Management LLC boosted its holdings in shares of Health Catalyst by 816.8% in the first quarter. AQR Capital Management LLC now owns 168,344 shares of the company's stock worth $763,000 after acquiring an additional 149,981 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Health Catalyst by 7.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company's stock valued at $163,000 after purchasing an additional 2,624 shares during the period. Focus Partners Wealth purchased a new stake in Health Catalyst during the 1st quarter worth about $46,000. Geode Capital Management LLC boosted its stake in Health Catalyst by 11.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company's stock worth $6,269,000 after purchasing an additional 169,580 shares during the period. Finally, Rhumbline Advisers grew its holdings in Health Catalyst by 13.5% during the 2nd quarter. Rhumbline Advisers now owns 101,986 shares of the company's stock valued at $384,000 after buying an additional 12,127 shares in the last quarter. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst NASDAQ: HCAT is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst's offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.